oyavas®

ACTIVE PRINCIPLE:
bevacizumab

INDICATION:

Colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer

DATE:
08/04/2021

STATUS:
Authorized

MORE INFORMATION